No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection | Zendy

Andrea L. Cathcart | Zendy; Henry LikYuen Chan | Zendy; Neeru Bhardwaj | Zendy; Yang Liu | Zendy; Patrick Marcellin | Zendy; Calvin Q. Pan | Zendy; S. Shalimar | Zendy; Marı́a Buti | Zendy; Stephanie Cox | Zendy; Bandita Parhy | Zendy; Eric S. Zhou | Zendy; Ross Martin | Zendy; Silvia Chang | Zendy; Lanjia Lin | Zendy; John F. Flaherty | Zendy; Kathryn M. Kitrinos | Zendy; Anuj Gaggar | Zendy; Namiki Izumi | Zendy; YoungSuk Lim | Zendy

Open Access

No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection

Author(s) -

Andrea L. Cathcart,

Henry LikYuen Chan,

Neeru Bhardwaj,

Yang Liu,

Patrick Marcellin,

Calvin Q. Pan,

S. Shalimar,

Marı́a Buti,

Stephanie Cox,

Bandita Parhy,

Eric S. Zhou,

Ross Martin,

Silvia Chang,

Lanjia Lin,

John F. Flaherty,

Kathryn M. Kitrinos,

Anuj Gaggar,

Namiki Izumi,

YoungSuk Lim

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01064-18

Subject(s) - tenofovir alafenamide , viremia , hepatitis b virus , medicine , virology , drug resistance , hepatitis b , hbeag , gastroenterology , biology , virus , viral load , hbsag , genetics , antiretroviral therapy

Tenofovir alafenamide (TAF) has shown equivalent efficacy and improved safety profiles for patients with chronic hepatitis B (CHB) compared to tenofovir disoproxil fumarate (TDF). However, limited data are available for its resistance profiles.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research